• Jim Chilcott, Chris McCabe, Paul Tappenden, Anthony O'Hagan, Nicola J Cooper, Keith Abrams, Karl Claxton, David H Miller, and Cost Effectiveness of Multiple Sclerosis Therapies Study Group.
• School of Health and Related Research Rapid Reviews Group, School of Health and Related Research, University of Sheffield.
• BMJ. 2003 Mar 8;326(7388):522; discussion 522.

ObjectiveTo evaluate the cost effectiveness of four disease modifying treatments (interferon betas and glatiramer acetate) for relapsing remitting and secondary progressive multiple sclerosis in the United Kingdom.DesignModelling cost effectiveness.SettingUK NHS.ParticipantsPatients with relapsing remitting multiple sclerosis and secondary progressive multiple sclerosis.Main Outcome MeasuresCost per quality adjusted life year gained.ResultsThe base case cost per quality adjusted life year gained by using any of the four treatments ranged from pound 42,000 (66,469 dollars; 61,630 euro) to pound 98,000 based on efficacy information in the public domain. Uncertainty analysis suggests that the probability of any of these treatments having a cost effectiveness better than pound 20,000 at 20 years is below 20%. The key determinants of cost effectiveness were the time horizon, the progression of patients after stopping treatment, differential discount rates, and the price of the treatments.ConclusionsCost effectiveness varied markedly between the interventions. Uncertainty around point estimates was substantial. This uncertainty could be reduced by conducting research on the true magnitude of the effect of these drugs, the progression of patients after stopping treatment, the costs of care, and the quality of life of the patients. Price was the key modifiable determinant of the cost effectiveness of these treatments.

21 keywords...

hide…